An interventional study of MR-guided Linac in Pancreas Cancer, Lung Cancer and Renal Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute — 5 open to participants now, 7 under way, none of them phase 3. Pancreatic Neoplasms · Dana-Farber Cancer Institute.
Among the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 with no phase, and was the 19th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →5 of the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 65+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8
First in 1998; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 397 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 36 across the 23 interventional studies, 192 across the 2 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
2 of the studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04674267Dana-Farber Cancer InstituteResilience and Equity in Aging, Cancer, and Health (REACH) | 2026-12-31 |
| NCT05356117Dana-Farber Cancer InstituteResistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer.
The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer.
In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of allergic reactions attributed to gadolinium-based IV contrast.
-- Note: If a patient will not receive contrast, this is not applicable
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
SMART will be administered per each individual disease site standards
Radiation: MR-guided Linac
Radiation will be delivered on an MR-guided Linear Accelerator
Delivery Success Rate for SMART across multiple tumors-Phase I
Enrolling patients and delivering SMART on the MR Linac
Time frame: 1 year
Tumor visualization-Phase I
Assessing tumor using MR guidance before, during and after MR-guided treatment patient
Time frame: 1 Year
Plan creation-Phase I
Generating adaptive plans
Time frame: 1 Year
Rate of Improvement in Tumor Control-Phase II
Statistical power will be defined in each cohort individually and will be specific to each disease site tested.
Time frame: 1 Year
Number of Patients with Acute Toxicity-Phase I
Any related ≥ Grade 3 AE which is possibly, probably or definitely related to SMART
Time frame: 90 Days
Duration of treatment-Phase 1
Duration of treatment with goal of \>80% of cases treated within 90 minutes
Time frame: 90 Days
Number of treatment fractions-Phase1
Number of treatment fractions that would have resulted in unacceptably high dose (exceeding constraint) to an OAR without SMART
Time frame: 90 Days
Number of Participants with long term toxicity-Phase II
assessing long-term (12 month) toxicity in patients receiving SMART
Time frame: 365 Days
Disease Specific Survival Rate-Phase II
Kaplan-Meier curve estimates
Time frame: 365 Days
Overall Survival Rate-Phase II
Kaplan-Meier curve estimates
Time frame: 365
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Dr. Jonathan Leeman (jonathane_leeman@dfci.harvard.edu). The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: BWH - Contact the Partners Innovations team at http://www.partners.org/innovation
Started Oct 2019 (actual). Primary completion is estimated for Jun 2028, 104 months after the start.
Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 104 months is above that.
Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →